Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity

Emerging data highlight the critical role for the innate immune system in the progression of nonalcoholic fatty liver disease (NAFLD). Connexin 32 (Cx32), the primary liver gap junction protein, is capable of modulating hepatic innate immune responses and has been studied in dietary animal models of...

Full description

Bibliographic Details
Main Authors: Warren, Andrew, Bhatia, Sangeeta N.
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Language:English
Published: Wiley 2020
Online Access:https://hdl.handle.net/1721.1/124770
_version_ 1811092512351191040
author Warren, Andrew
Bhatia, Sangeeta N.
author2 Harvard University--MIT Division of Health Sciences and Technology
author_facet Harvard University--MIT Division of Health Sciences and Technology
Warren, Andrew
Bhatia, Sangeeta N.
author_sort Warren, Andrew
collection MIT
description Emerging data highlight the critical role for the innate immune system in the progression of nonalcoholic fatty liver disease (NAFLD). Connexin 32 (Cx32), the primary liver gap junction protein, is capable of modulating hepatic innate immune responses and has been studied in dietary animal models of steatohepatitis. In this work, we sought to determine the association of hepatic Cx32 with the stages of human NAFLD in a histologically characterized cohort of 362 patients with NAFLD. We also studied the hepatic expression of the genes and proteins known to interact with Cx32 (known as the connexome) in patients with NAFLD. Last, we used three independent dietary mouse models of nonalcoholic steatohepatitis to investigate the role of Cx32 in the development of steatohepatitis and fibrosis. In a univariate analysis, we found that Cx32 hepatic expression associates with each component of the NAFLD activity score and fibrosis severity. Multivariate analysis revealed that Cx32 expression most closely associated with the NAFLD activity score and fibrosis compared to known risk factors for the disease. Furthermore, by analyzing the connexome, we identified novel genes related to Cx32 that associate with NAFLD progression. Finally, we demonstrated that Cx32 deficiency protects against liver injury, inflammation, and fibrosis in three murine models of nonalcoholic steatohepatitis by limiting initial diet‐induced hepatoxicity and subsequent increases in intestinal permeability. Conclusion: Hepatic expression of Cx32 strongly associates with steatohepatitis and fibrosis in patients with NAFLD. We also identify novel genes associated with NAFLD and suggest that Cx32 plays a role in promoting NAFLD development. ©2018
first_indexed 2024-09-23T15:19:23Z
format Article
id mit-1721.1/124770
institution Massachusetts Institute of Technology
language English
last_indexed 2024-09-23T15:19:23Z
publishDate 2020
publisher Wiley
record_format dspace
spelling mit-1721.1/1247702022-09-29T14:11:55Z Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity Warren, Andrew Bhatia, Sangeeta N. Harvard University--MIT Division of Health Sciences and Technology Emerging data highlight the critical role for the innate immune system in the progression of nonalcoholic fatty liver disease (NAFLD). Connexin 32 (Cx32), the primary liver gap junction protein, is capable of modulating hepatic innate immune responses and has been studied in dietary animal models of steatohepatitis. In this work, we sought to determine the association of hepatic Cx32 with the stages of human NAFLD in a histologically characterized cohort of 362 patients with NAFLD. We also studied the hepatic expression of the genes and proteins known to interact with Cx32 (known as the connexome) in patients with NAFLD. Last, we used three independent dietary mouse models of nonalcoholic steatohepatitis to investigate the role of Cx32 in the development of steatohepatitis and fibrosis. In a univariate analysis, we found that Cx32 hepatic expression associates with each component of the NAFLD activity score and fibrosis severity. Multivariate analysis revealed that Cx32 expression most closely associated with the NAFLD activity score and fibrosis compared to known risk factors for the disease. Furthermore, by analyzing the connexome, we identified novel genes related to Cx32 that associate with NAFLD progression. Finally, we demonstrated that Cx32 deficiency protects against liver injury, inflammation, and fibrosis in three murine models of nonalcoholic steatohepatitis by limiting initial diet‐induced hepatoxicity and subsequent increases in intestinal permeability. Conclusion: Hepatic expression of Cx32 strongly associates with steatohepatitis and fibrosis in patients with NAFLD. We also identify novel genes associated with NAFLD and suggest that Cx32 plays a role in promoting NAFLD development. ©2018 2020-04-21T19:29:46Z 2020-04-21T19:29:46Z 2018-07 2019-05-09T17:28:51Z Article http://purl.org/eprint/type/JournalArticle 2471-254X https://hdl.handle.net/1721.1/124770 Luther, Jay, et al., "Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity." Hepatology communications 2, 7 (July 2018): p. 786-97 doi 10.1002/HEP4.1179 ©2018 Author(s) en 10.1002/HEP4.1179 Hepatology communications Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Wiley Hepatology Communications
spellingShingle Warren, Andrew
Bhatia, Sangeeta N.
Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
title Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
title_full Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
title_fullStr Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
title_full_unstemmed Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
title_short Hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
title_sort hepatic connexin 32 associates with nonalcoholic fatty liver disease severity
url https://hdl.handle.net/1721.1/124770
work_keys_str_mv AT warrenandrew hepaticconnexin32associateswithnonalcoholicfattyliverdiseaseseverity
AT bhatiasangeetan hepaticconnexin32associateswithnonalcoholicfattyliverdiseaseseverity